C12Y603/05004

METHODS OF IDENTIFYING GENETIC VARIANTS

The present invention relates to identification of an abnormal splice site. Provided are methods of identifying an abnormal splice site. Methods of classifying the risk of abnormal splicing of a splice site are also provided. Databases for use in the methods provided herein are also disclosed.

Microbiome-based informed method to formulate live biotherapeutics

Methods of formulating live biotherapeutics are disclosed in which a deficiency or excess of a specific bacterial strain in a person's microbiome is identified by comparing a gene-specific characterization of the person's microbiome against a comprehensive, non-redundant reference gene catalog, and the biotherapeutic is formulated by selecting bacteria to address the deficiency or excess. Embodiments include the formulation of live biotherapeutics for improving the health of a person's vaginal microbiome, i.e. using a vaginal reference gene catalog, and may be suitable for ameliorating, treating, or preventing a malignancy such as a cancer of the female genitourinary system.

Microbiome-based informed method to formulate live biotherapeutics
20200227139 · 2020-07-16 ·

Methods of formulating live biotherapeutics are disclosed in which a deficiency or excess of a specific bacterial strain in a person's microbiome is identified by comparing a gene-specific characterization of the person's microbiome against a comprehensive, non-redundant reference gene catalog, and the biotherapeutic is formulated by selecting bacteria to address the deficiency or excess. Embodiments include the formulation of live biotherapeutics for improving the health of a person's vaginal microbiome, i.e. using a vaginal reference gene catalog, and may be suitable for ameliorating, treating, or preventing a malignancy such as a cancer of the female genitourinary system.

WHEAT PLANTS WITH REDUCED FREE ASPARAGINE CONCENTRATION IN GRAIN

The disclosure relates to compositions and methods for reducing free asparagine concentration in the grain of wheat plants. The compositions comprise wheat plants, plant parts, plant cells, and seeds comprising a loss-of-function mutation in at least one endogenous ASPARAGINE SYNTHETASE 2 (ASN2) gene. The grain of wheat plants has reduced acrylamide-forming potential. Low acrylamide products produced from the grain are also provided.

METABOLIC SELECTION VIA ASPARAGINE BIOSYNTHESIS PATHWAY

The present disclosure provides an isolated mammalian cell comprising a reduced or eliminated expression of Asparagine Synthetase (ASNS). Further provided are methods for preparing such cells and methods for using such cells for the production of recombinant proteins.

METABOLIC SELECTION VIA THE SERINE BIOSYNTHESIS PATHWAY

The present disclosure provides an isolated mammalian cell comprising a reduced or eliminated expression of Phosphoserine Phosphatase (PSPH). Further provided are methods for preparing such cells and methods for using such cells for the production of recombinant proteins.